MBX Biosciences has added to the recent flurry of IPO filings. The biotech, which filed its paperwork weeks after raising $63.5 million privately, is seeking funding to take a would-be challenger to ...
MBX Biosciences Inc. is a company in a hurry. Just three weeks after announcing it had raised $63.5 million in a round of private funding, the Carmel-based company has filed paperwork to go public.
MBX Biosciences Inc. has submitted an IND application to the FDA for MBX-4291, a long-acting glucagon-like peptide-1 (GLP-1)/ glucose-dependent insulinotropic polypeptide (GIP) receptor co-agonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results